Last reviewed · How we verify
PWT-143
At a glance
| Generic name | PWT-143 |
|---|---|
| Sponsor | MEI Pharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma (PHASE1, PHASE2)
- Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PWT-143 CI brief — competitive landscape report
- PWT-143 updates RSS · CI watch RSS
- MEI Pharma, Inc. portfolio CI